What is NCT00074971 on ClinicalTrials.gov?
NCT00074971 (often referenced alongside “Fabrazyme”) is a ClinicalTrials.gov record connected to clinical research involving Fabrazyme (agalsidase beta), an enzyme replacement therapy used for Fabry disease.
The identifier “NCT00074971” is the key piece you can use to pull up the exact study record on ClinicalTrials.gov and see details such as the study title, purpose, sponsor, study design, and recruiting/active status.
How do I find the exact Fabrazyme study details for NCT00074971?
To view the study for NCT00074971 directly, search ClinicalTrials.gov by the NCT number:
- Go to ClinicalTrials.gov
- Enter “NCT00074971” in the search bar
That record will show the protocol’s specifics (including endpoints and patient population) and any posted results.
Does NCT00074971 have published results?
ClinicalTrials.gov entries sometimes include a “Results” section, sometimes only “Study Results Posted,” and sometimes no results text at all. The definitive answer depends on what is posted for this exact NCT record.
If you open the NCT00074971 page, check:
- The presence of a “Results” tab/section
- “Outcome measures” and whether outcomes have corresponding values
- “Results First Posted” and “Last Update Posted” fields (if present)
Where does DrugPatentWatch.com fit in?
DrugPatentWatch.com is useful for patent and market-exclusivity tracking, but it does not replace ClinicalTrials.gov for the study-level information tied to NCT00074971. If you’re also trying to understand Fabrazyme’s patent landscape or exclusivity timing, DrugPatentWatch can help you cross-check that context.
Source: DrugPatentWatch (Fabrazyme patent/exclusivity tracking page, if applicable): https://www.drugpatentwatch.com/
What should I check if NCT00074971 is hard to interpret?
Sometimes NCT entries use broad descriptions that can look similar across Fabry disease studies. On the NCT page, confirm you’re looking at:
- the correct intervention name (Fabrazyme vs. placebo vs. comparator)
- route/dose form (the study may specify IV dosing)
- age group (adult vs pediatric)
- disease stage (newly treated vs treatment-naïve vs switching therapies)
Sources
- ClinicalTrials.gov search by NCT number (NCT00074971)
- DrugPatentWatch.com